Matrix metalloproteinases: Drug targets for myocardial infarction

Andriy Yabluchanskiy, Yaojun Li, Robert J. Chilton, Merry L. Lindsey

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

Original languageEnglish (US)
Pages (from-to)276-286
Number of pages11
JournalCurrent drug targets
Issue number3
StatePublished - 2013
Externally publishedYes


  • Extracellular matrix
  • Left ventricle
  • Left ventricle remodeling
  • Matrix metalloproteinases
  • Myocardial infarction

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Matrix metalloproteinases: Drug targets for myocardial infarction'. Together they form a unique fingerprint.

Cite this